Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status

被引：43

作者：

Bokemeyer, C.

Kohne, C.

Rougier, P.

Stroh, C.

Schlichting, M.

Van Cutsem, E.

机构：

[1] Univ Klinikum Eppendorf, Hamburg, Germany

[2] Oncol Klinikum Oldenburg, Oldenburg, Germany

[3] Hop Ambroise Pare, Boulogne, France

[4] Merck KGaA, Darmstadt, Germany

[5] Univ Hosp Gasthuisberg, Dept Digest Oncol, B-3000 Louvain, Belgium

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.3506

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3506

引用

页数：1